---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-125566"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2023-12-13T23:59:59+00:00"
generated_at: "2026-06-07T13:32:10.322842+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Black Diamond reports Phase 1 topline data for BDTX-1535 in recurrent GBM; durable stabilization seen

## Summary
- 22 evaluable patients: 3 on therapy >10 months, 1 >6 months, 5 >4 months; historical PFS is 2–4 months.
- 19 measurable disease patients: 1 confirmed partial response (200 mg QD) and 8 stable disease per RANO criteria.
- No new safety signals; AEs were Grade 1–2 diarrhea and rash, consistent with EGFR TKI class.
- One patient remains on 100 mg QD for >15 months after progression on temozolomide at 3 months.
- Company plans to present dose escalation results at a medical meeting in Q2 2024; window-of-opportunity trial enrolling.

## SEC filing metadata
- accession: 0001104659-23-125566
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2023-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000110465923125566/0001104659-23-125566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000110465923125566/tm2332757d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-125566
- JSON: https://secwatch.observer/filing/0001104659-23-125566.json
- Plain text: https://secwatch.observer/filing/0001104659-23-125566.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.